Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity-Reference-Cited by-同舟云学术

Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Published:2020-03-04 Issue:6 Volume:63 Page:3327-3347
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Yang¹,Chen Xing¹,Yan Yaoyao¹,Zhu Xiaochen¹,Liu Mingming¹²,Liu Xinhua¹^ORCID

Affiliation:

1. School of Pharmacy, Anhui Medical University, Hefei 230032, China

2. Anhui Chem-Bright Bioengineering Co., Ltd., Huaibei 235025, China

Funder

National Natural Science Foundation of China

Anhui Educational Committee

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b02121

Reference42 articles.

1. Cyclins and cdks in development and cancer: a perspective

2. Cdks, cyclins and CKIs: roles beyond cell cycle regulation

3. Cyclin-dependent kinases

4. Targeting cancer with small molecule kinase inhibitors

5. The ins and outs of selective kinase inhibitor development

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

2. Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment;Bioorganic Chemistry;2024-08

3. Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design;Journal of Medicinal Chemistry;2024-06-29

4. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02

5. Cyclin-Dependent kinase 9 (CDK9) inhibitor Atuveciclib ameliorates Imiquimod-Induced Psoriasis-Like dermatitis in mice by inhibiting various inflammation factors via STAT3 signaling pathway;International Immunopharmacology;2024-03